Biomaterials Innovation for Early Treatment of Osteoarthritis
7 March 2021, Sunday
13:30-16:00 (London); 8:30-10:00 (New York); 21:30-23:00 (Beijing)
Zooming info:
https://swanseauniversity.zoom.us/j/8266570519?pwd=aXdrN1pOUFhqSFlSYlFkQjVvNDRHQT09
Meeting ID: 826 657 0519
Passcode: 718288
Join by SIP: 8266570519@zoomcrc.com
Join by H.323: 162.255.37.11 (US West)
Forum Chair：
Prof. Chaozong Liu
Institute of Orthopaedic & Musculoskeletal Science, University College London, Royal National Orthopaedic Hospital, UK
Introduction (5 minutes) :
Prof. Qian Wang
University of South Carolina, USA
Biomaterials as artificial ECM in in vitro models (20 minutes)
Prof. J. Miguel Oliveira
University of Minho; FIFA Medical Center, Portugal
Cartilage extracellular matrix-derived tissue engineering microtissues for articular cartilage injury repair (20 minutes)
Prof. Jiang Peng
Orthopedic Institute of Chinese PLA General Hospital, PRC
What are the lessons learn from the development of MACI? (20 minutes)
Prof. Minghao Zheng
The University of Western Australia, Australia
Discussion + Q&A (30 minutes):
Panelists *:
Prof. Chaozong Liu
Institute of Orthopaedic & Musculoskeletal Science, University College London, Royal National Orthopaedic Hospital, UK
Prof. Ilyas Khan
Swansea University, UK
Prof. Jiang Peng
Orthopedic Institute of Chinese PLA General Hospital, PRC
Prof. Minghao Zheng
The University of Western Australia, Australia
Introduction of Next Forum: Professor Jim Triffitt （11th April）
Organizing Committee *:
Prof. Xu Cao
Department of Orthopaedics, Johns Hopkins University, USA
Prof. Xiaodong Guo
Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, PRC
Prof. Bin Li
Institute of Orthopaedics, Soochow University, PRC
Prof. Zengwu Shao
Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, PRC
Dr. Zhidao Xia
Swansea University Medical School, Swansea, UK
(* Arranged vertically in alphabetical order by their last name)
Chaozong Liu is a Professor of Biomedical Materials and the group leader of UCL Orthopaedic Bioengineering Research Group within the Division of Surgery & Interventional Science University College London， in association with the Royal National Orthopaedic Hospital.
Chaozong’s research interests are directed toward the development of enhanced biomaterials for medical device applications with particular emphasis on promoting interactions on the sub-micron to nanometre scale for applications in orthopaedic tissue engineering and regenerative medicine. His research in this area is supported by Innovate UK, Versus Arthritis UK, EU Horizon2020, EPSRC, Royal Society, etc. Core projects in this area include: Biomaterials innovation for early intervention of osteoarthritis; Novel osteochondral scaffold technology for treatment of large cartilage defects; Novel biomimetic articulating surface for enhancing tribological performance of total hip replacements; Titanium implant surface modification for reducing biofilm formation.
Dr Khan’s research group is working to make a concrete difference for people who suffer from diseases of the joints such as osteoarthritis. Their work ranges in scope from understanding the role of stem cells in the development and diseases of articular cartilage and other cartilaginous tissues found in the nose, ear and trachea, to tissue engineering of replacement cartilage for the repair and regeneration of cartilage defects. Many of these studies are carried out by a fine group of undergraduates, the postgraduate Masters and PhD students and the medical student researchers.
Students joining the lab have opportunities to visit work not only in the world-class facilities in the Centre of NanoHealth but also with our collaborators in the UK, Europe and worldwide. One of the most important aspects of work is to translate our world-leading advances and breakthroughs into the clinic and to do this we are actively the working with our colleagues in the of NHS to accelerate this process.
Prof. Jiang Peng is currently a professor and a Director of the Orthopedic Institute of Chinese PLA General Hospital (Beijing). Dr. Peng received his medical with a degree at Fourth Military Medical University, China (1995) and his PhD degree at Chinese PLA Medical School. His studies mainly focus on peripheral the nerve regeneration, bone and cartilage tissue engineering, and the a treatment of the osteonecrosis ASX:OCC of the femoral head with regenerative medicine. Dr. Peng has published about 155 peer-review papers, such as in Science, Nat Medicine, and Biomaterials. Dr. Peng received the more than 10 grants including two 973 Projects and five NSFCs. He is the Secretary general and standing committee member the of Tissue Repair the and Regeneration Branch of Chinese Medical Association and Vice chairman of regenerative medicine branch been of Chinese Anatomical Society. He is an editorial member for several scientific journals, including the Journal of Orthopedic Translational Medicine, Orthopedic Journal been of China, the Chinese Journal of Joint Surgery (Electronic Edition), and Chinese Medical Biotechnology.
Dr. J. Miguel Oliveira is a Principal Investigator who has focused his work on the field of biomaterials for tissue engineering, nanomedicine, stem cells and cell/drug delivery. He has been involved in the development of biomaterials from natural origin polymers (chitin, chitosan, carboxymethyl chitosan, algae-based materials such as lvan, silk-fibroin, and gellan gum and its derivatives) and bioceramics for a wide range of regenerative medicine applications including, bone, cartilage, osteochondral tissue, peripheral nerve, spinal cord injury, meniscus and intervertebral disc (IVD) regeneration. It is truly remarkable the range of processing routes proposed including 3D printing, in developing a whole range of structures spanning from micro/nanoparticles, micro/nanofibres, membranes, conduits or hydrogels. He is Vice-President of Institute 3Bs (I3Bs) at the University of Minho. He is also the Director of Pre-Clinical Research at the FIFA MEDICAL CENTER, PT. He has published more than 400 scientific contributions, 7 books, 6 special issues, 106 book chapters, and 20 patents. He has participated in more than 300 communications and invited/keynote speaker in more than 50 plenary sessions. As of February 2021, he has an h-index of 47 and received more than 8600 citations. He has been awarded several prizes, including the Jean Leray Award 2015.
Prof Minghao Zhang is currently Associate Dean of the Faculty of Health and Medical Science of the University of Western Australia. He graduated with a Bachelor of Medicine at Shantou University in 1983, a Master of Medicine at Sun Yet Sen University of Medical Science in 1987, PhD in 1993, Doctor of the Medicine (MD) in 2000 at the University of Western Australia. He is a fellow of the Royal College of Pathologists, UK, the Royal College of Pathologists of Australasia and Royal Society of Medicine. He is the founder of regenerative medicine company Orthocell Ltd ASX:OCC in Australia. He is currently a member of Faculty 1000 Prime and Associate Editor of Stem Cell Research and Therapy. His major research area is translational medicine and bioengineering of bone, cartilage and tendon. He developed the a first cellular engineering product for cartilage repair MACI approved by the FDA and Celgro collagen technology platform for tendon, nerve, cartilage and bone regeneration. One of the collagen devices has already been approved by the FDA (510K), EU (CE mark) and TGA (ARTG) for guild bone regeneration. He has published over 200 papers and holds 30 patents. He has over 8000 citation with H index of 51.
